Zenflow弹簧系统治疗良性前列腺增生:ZEST初步研究24个月结果
三项单臂多中心前瞻性初步研究(2018-2021年,四国)合并分析Zenflow弹簧系统治疗梗阻性BPH的可行性、安全性和有效性。72例患者均成功植入,围手术期无严重不良事件,3个月IPSS、IPSS-QoL和Qmax分别改善49%、47%和27%,并持续至24个月。
要点
- Zenflow弹簧系统可保留组织,72例均成功植入,围手术期无严重不良事件。
- 3个月IPSS平均变化-10.71,IPSS-QoL -2.1,Qmax +2.86 mL/s,均显著改善。
- 上述改善持续至24个月,相对基线改善分别为48%、55%和32%。
核心结论
- 24个月时,Zenflow弹簧系统治疗BPH相关下尿路症状较基线有立即、显著且持久的改善,支持其作为微创、保留组织的治疗选择。
研究设计与样本
- 三项单臂、多中心、前瞻性初步研究于2018-2021年在四个国家开展,设计相似,数据合并分析。
- 纳入72例≥45岁、IPSS>13、Qmax 5-15 mL/s、前列腺体积25-80 cc、前列腺尿道长度25-45 mm、排尿量≥125 mL的男性。
- 主要终点为术后3个月IPSS变化;次要终点包括IPSS-QoL和Qmax;随访至24个月。
主要发现
- 所有72例研究参与者均成功植入弹簧植入物,围手术期无严重不良事件。
- 3个月时IPSS平均变化-10.71(95%CI:-12.90,-8.51,p<0.001),IPSS-QoL -2.1(95%CI:-2.61,-1.58,p<0.001),Qmax +2.86(95%CI:1.68,4.04,p<0.001)。
- 3个月时IPSS、IPSS-QoL和Qmax相对基线分别改善49%、47%和27%。
- 上述改善持续至24个月,IPSS、IPSS-QoL和Qmax相对基线分别改善48%、55%和32%。
临床怎么用
- 对于药物治疗效果不佳或不耐受、且不愿接受切割或消融类MIST的BPH患者,Zenflow弹簧系统可作为微创、保留组织的选项。
- 术后3个月即可观察到显著症状和功能改善,且效果可持续至24个月。
局限性
- 三项均为单臂、前瞻性初步研究,无对照组,样本量有限(72例),结论需更大规模随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benign Prostatic Hyperplasia (BPH) affects more than half of men over age 50, yet current treatment options are limited to medications that cause bothersome side effects or surgical procedures, including minimally invasive surgical therapies (MIST) that involve piercing, cutting, or burning tissue, often leading to discomfort and recovery concerns. The Zenflow Spring System® provides a tissue-preserving alternative that offers symptom relief with quicker recovery and less procedural discomfort. METHODS: Three single-arm, multicenter, prospective pilot studies with similar trial designs were conducted from 2018-2021 across four countries and data were combined to evaluate the feasibility, safety, and effectiveness of the Spring System in relieving symptoms of obstructive BPH. Men ≥ 45 years with moderate-to-severe symptoms (International Prostate Symptom Score (IPSS ) >13), peak urinary flow rate (QMax) between 5 and 15 mL/s, prostate volume between 25 and 80 cc, prostatic urethral length between 25 and 45 mm, and voided volume of at least ≥ 125 mL were enrolled. The primary endpoint was symptom improvement 3 months post-procedure, measured by change in IPSS. Secondary endpoints included IPSS-QoL, and functional improvement measured by Qmax. Follow-up visits occurred through 24 months. RESULTS: Successful implantation of the Spring Implant was achieved in all 72 study participants, with no perioperative serious adverse events. At 3 months, mean change from baseline was -10.71 (95% CI: -12.90, -8.51, p < 0.001) for IPSS, -2.1 (95% CI: -2.61, -1.58, p < 0.001) for IPSS-QoL, and 2.86 (95% CI: 1.68, 4.04, p < 0.001) for Qmax, corresponding to 49%, 47%, and 27% improvements, respectively. These improvements were sustained through 24 months, with 48%, 55%, and 32% improvement relative to baseline in IPSS, IPSS-QoL, and Qmax, respectively. CONCLUSIONS: At 24-months, treatment with the Spring System resulted in immediate, significant, and durable improvements compared with baseline, supporting its role as a minimally invasive, tissue-preserving treatment option for men with lower urinary tract symptoms secondary to BPH. TRIAL REGISTRATION: NCT03595735, NCT03577236, NCT04309695.
引用
- Gilling P, Chin P, Anderson P, et al. Zenflow spring system for benign prostatic hyperplasia - 24 month outcomes of the ZEST pilot studies. Prostate Cancer Prostatic Dis. 2026. PMID: 42265447. doi:10.1038/s41391-026-01126-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。